加拿大青少年和年轻成人骨髓增殖性肿瘤患者队列的临床特征与长期结局:加拿大MPN组研究
该研究回顾性分析了加拿大8个中心诊断年龄≤45岁的609例骨髓增殖性肿瘤患者,中位总生存期为36.8年;诊断前纤维化或明显原发性骨髓纤维化与最低总生存期和最高急变/骨髓纤维化转化风险相关;血栓并发症发生率为24%,包括内脏循环血栓形成9%;除JAK2/MPL/CALR外的突变在疾病初期不常见(12%),但可能预测向ET/PV后骨髓纤维化转化。
要点
- 诊断年龄≤45岁的骨髓增殖性肿瘤患者中,诊断前纤维化或明显原发性骨髓纤维化与最低总生存期和最高急变/骨髓纤维化转化风险相关。
- 血栓并发症发生率为24%,包括内脏循环血栓形成9%。
- 除JAK2/MPL/CALR外的突变在疾病初期不常见(12%),但可能预测向ET/PV后骨髓纤维化转化。
核心结论
- 在加拿大青少年和年轻成人骨髓增殖性肿瘤患者队列中,诊断前纤维化或明显原发性骨髓纤维化与最低总生存期和最高急变/骨髓纤维化转化风险相关。
- 除JAK2/MPL/CALR外的突变在疾病初期不常见(12%),但数据表明它们可能预测向ET/PV后骨髓纤维化转化。
研究设计与样本
- 研究为回顾性综述,纳入加拿大8个中心诊断年龄≤45岁的骨髓增殖性肿瘤患者,共609例。
主要发现
- 中位总生存期为36.8年。
- 诊断前纤维化或明显原发性骨髓纤维化与最低总生存期和最高急变/骨髓纤维化转化风险相关。
- 血栓并发症发生率为24%,包括内脏循环血栓形成9%。
- 除JAK2/MPL/CALR外的突变在疾病初期不常见(12%),但数据表明它们可能预测向ET/PV后骨髓纤维化转化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs) are a group of chronic hematologic malignancies that lead to morbidity and early mortality due to thrombotic complications and progression to acute leukemia. Clinical and mutational risk factors have been demonstrated to predict outcomes in patients with MPNs and are used commonly to guide therapeutic decisions, including allogenic stem cell transplant, in myelofibrosis. Adolescents and young adults (AYA, age ≤45 years) comprise less than 10% of all MPN patients and have unique clinical and therapeutic considerations. The prevalence and clinical impact of somatic mutations implicated in myeloid disease has not been extensively examined in this population. We conducted a retrospective review of patients evaluated at eight Canadian centers for MPN patients diagnosed at ≤45 years of age. In total, 609 patients were included in the study, with median overall survival of 36.8 years. Diagnosis of prefibrotic or overt PMF is associated with the lowest OS and highest risk of AP/BP transformation. Thrombotic complications (24%), including splanchnic circulation thrombosis (9%), were frequent in the cohort. Mutations in addition to those in JAK2/MPL/CALR are uncommon in the initial disease phase in our AYA population (12%); but our data indicate they may be predictive of transformation to post-ET/PV myelofibrosis.
引用
- England JT, Szuber N, Sirhan S, et al. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study. Leukemia. 2024. PMID: 38321107. doi:10.1038/s41375-024-02155-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。